お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
980853

トリプルネガティブ乳がん (TNBC) 治療の世界市場:併用療法への注目が市場拡大を促進

Global Market Study on Triple-Negative Breast Cancer Treatment: Rising Focus on Combination Therapies Aiding Market Expansion

出版日: | 発行: Persistence Market Research | ページ情報: 英文 224 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
トリプルネガティブ乳がん (TNBC) 治療の世界市場:併用療法への注目が市場拡大を促進
出版日: 2021年01月12日
発行: Persistence Market Research
ページ情報: 英文 224 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のトリプルネガティブ乳がん (TNBC) 治療市場について調査分析し、市場力学、市場構造、市場分析と予測、地域別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場カバレッジ/分類法
  • 市場の定義/範囲/制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 製品開発動向
  • 主要規制

第4章 市場の背景

  • マクロ経済要因
  • 予測要因:関連性と影響
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会分析
  • バリューチェーン分析

第5章 COVID-19の影響分析

    • 現在のCOVID-19の統計と予想される将来の影響
    • 現在のGDPの予測と予想される影響
    • 2008年の経済分析と比較した現在の経済予測
    • COVID-19と影響分析
    • 予想される回復の四半期
    • 回復シナリオ:短期・中期・長期の影響

第6章 主要成功要因

  • 製品の採用/使用分析
  • 主要プロモーション戦略
  • 疾患の疫学:主要地域
  • 償還ガイドライン

第7章 世界のトリプルネガティブ乳がん (TNBC) 治療市場の価格分析

  • 地域の価格分析:製品タイプ別
  • 価格の内訳
    • メーカーレベルの価格
    • ディストリビューターレベルの価格

第8章 世界のトリプルネガティブ乳がん (TNBC) 治療市場の需要分析と予測

  • 過去の市場分析
  • 現在・将来の市場予測
    • 前年比成長率動向分析

第9章 世界のトリプルネガティブ乳がん (TNBC) 治療市場分析と予測:薬剤の種類別

  • イントロダクション/主な調査結果
  • 過去の市場分析:薬剤の種類別
  • 現在・将来の市場と予測:薬剤の種類別
    • ドキソルビシン
    • シクロホスファミド
    • パクリタキセル
    • ドセタキセル
    • カルボプラチン/シスプラチン
    • その他
  • 市場の魅力分析:薬剤の種類別

第10章 世界のトリプルネガティブ乳がん (TNBC) 治療市場分析と予測:流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場分析:流通チャネル別
  • 現在・将来の市場分析と予測:流通チャネル別
    • 病院
    • がん研究機関
    • リテールクリニック
  • 市場の魅力分析:流通チャネル別

第11章 世界のトリプルネガティブ乳がん (TNBC) 治療市場分析と予測:地域別

  • イントロダクション
  • 過去の市場分析:地域別
  • 現在の市場分析と予測:地域別
    • 北米
    • ラテンアメリカ
    • 欧州
    • 南アジア
    • 東アジア
    • オセアニア
    • 中東・アフリカ
  • 市場の魅力分析:地域別

第12章 北米のトリプルネガティブ乳がん (TNBC) 治療市場分析と予測

第13章 ラテンアメリカのトリプルネガティブ乳がん (TNBC) 治療市場分析と予測

第14章 欧州のトリプルネガティブ乳がん (TNBC) 治療市場分析と予測

第15章 南アジアのトリプルネガティブ乳がん (TNBC) 治療市場分析と予測

第16章 東アジアのトリプルネガティブ乳がん (TNBC) 治療市場分析と予測

第17章 オセアニアのトリプルネガティブ乳がん (TNBC) 治療市場分析と予測

第18章 中東・アフリカのトリプルネガティブ乳がん (TNBC) 治療市場分析と予測

第19章 主要国・新興国のトリプルネガティブ乳がん (TNBC) 治療市場分析と予測

第20章 市場構造分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合分析
    • AstraZeneca plc.
    • Pfizer, Inc.
    • F. Hoffman - La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Mylan N.V.
    • Eli Lilly and Company
    • Celgene Corporation
    • Sanofi S.A.
    • Johnson & Johnson Services, Inc.

第22章 前提条件と略語

第23章 調査手法

図表

List of Tables

  • Table 01: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
  • Table 02: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
  • Table 03: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Region
  • Table 04: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
  • Table 05: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
  • Table 06: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
  • Table 07: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
  • Table 08: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
  • Table 09: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
  • Table 10: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
  • Table 11: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
  • Table 12: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
  • Table 13: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
  • Table 14: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
  • Table 15: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
  • Table 16: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
  • Table 17: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
  • Table 18: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
  • Table 19: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
  • Table 20: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
  • Table 21: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel
  • Table 22: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country
  • Table 23: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type
  • Table 24: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

List of Figures

  • Figure 01: Global Triple-Negative Breast Cancer Treatment Market Value Analysis and Forecast, 2020-2030 (US$ Mn)
  • Figure 02: Global Triple-Negative Breast Cancer Treatment Market Absolute $ Opportunity (US$ Mn), 2015-2019
  • Figure 03: Global Triple-Negative Breast Cancer Treatment Market Absolute $ Opportunity (US$ Mn), 2020-2030
  • Figure 04: Global Triple-Negative Breast Cancer Treatment Market Share Analysis (%) By Drug Type, 2018 & 2026
  • Figure 05: Global Triple-Negative Breast Cancer Treatment Market Y-o-Y Growth (%) By Drug Type, 2020-2030
  • Figure 06: Global Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Drug Type
  • Figure 07: Global Triple-Negative Breast Cancer Treatment Market Share Analysis (%) By Distribution Channel, 2018 & 2026
  • Figure 08: Global Triple-Negative Breast Cancer Treatment Market Y-o-Y Growth (%) By Distribution Channel, 2020-2030
  • Figure 09: Global Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Distribution Channel
  • Figure 10: Global Triple-Negative Breast Cancer Treatment Market Share Analysis (%) By Region, 2020 & 2030
  • Figure 11: Global Triple-Negative Breast Cancer Treatment Market Y-o-Y Growth (%) By Region, 2020-2030
  • Figure 12: Global Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Region
  • Figure 13: North America Triple-Negative Breast Cancer Treatment Market Value Share, By Drug Type (2019)
  • Figure 14: North America Triple-Negative Breast Cancer Treatment Market Value Share, By Distribution Channel (2019)
  • Figure 15: North America Triple-Negative Breast Cancer Treatment Market Value Share, By Country (2019)
  • Figure 16: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis, 2015-2019
  • Figure 17: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2030
  • Figure 18: North America Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Drug Type
  • Figure 19: North America Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Distribution Channel
  • Figure 20 : North America Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Country
  • Figure 21: Latin America Triple-Negative Breast Cancer Treatment Market Value Share, By Drug Type (2019)
  • Figure 22: Latin America Triple-Negative Breast Cancer Treatment Market Value Share, By Distribution Channel (2019)
  • Figure 23: Latin America Triple-Negative Breast Cancer Treatment Market Value Share, By Country (2019)
  • Figure 24: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis, 2015-2019
  • Figure 25: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2030
  • Figure 26: Latin America Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Drug Type
  • Figure 27: Latin America Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Distribution Channel
  • Figure 28: Latin America Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Country
  • Figure 29: Europe Triple-Negative Breast Cancer Treatment Market Value Share, By Drug Type (2019)
  • Figure 30: Europe Triple-Negative Breast Cancer Treatment Market Value Share, By Distribution Channel (2019)
  • Figure 31: Europe Triple-Negative Breast Cancer Treatment Market Value Share, By Country (2019)
  • Figure 32: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis, 2015-2019
  • Figure 33: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2030
  • Figure 34: Europe Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Drug Type
  • Figure 35 : Europe Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Distribution Channel
  • Figure 36: Europe Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Country
  • Figure 37: South Asia Triple-Negative Breast Cancer Treatment Market Value Share, By Drug Type (2019)
  • Figure 38: South Asia Triple-Negative Breast Cancer Treatment Market Value Share, By Distribution Channel (2019)
  • Figure 39: South Asia Triple-Negative Breast Cancer Treatment Market Value Share, By Country (2019)
  • Figure 40: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis, 2015-2019
  • Figure 41: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2030
  • Figure 42: South Asia Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Drug Type
  • Figure 43: South Asia Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Distribution Channel
  • Figure 44: South Asia Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Country
  • Figure 45: East Asia Triple-Negative Breast Cancer Treatment Market Value Share, By Drug Type (2019)
  • Figure 46: East Asia Triple-Negative Breast Cancer Treatment Market Value Share, By Distribution Channel (2019)
  • Figure 47: East Asia Triple-Negative Breast Cancer Treatment Market Value Share, By Country (2019)
  • Figure 48: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis, 2015-2019
  • Figure 49: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2030
  • Figure 50 : East Asia Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Drug Type
  • Figure 51: East Asia Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Distribution Channel
  • Figure 52: East Asia Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Country
  • Figure 53: Oceania Triple-Negative Breast Cancer Treatment Market Value Share, By Drug Type (2019)
  • Figure 54: Oceania Triple-Negative Breast Cancer Treatment Market Value Share, By Distribution Channel (2019)
  • Figure 55: Oceania Triple-Negative Breast Cancer Treatment Market Value Share, By Country (2019)
  • Figure 56: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis, 2015-2019
  • Figure 57: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2030
  • Figure 58 : Oceania Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Drug Type
  • Figure 59: Oceania Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Distribution Channel
  • Figure 60: Oceania Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Country
  • Figure 61: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value Share, By Drug Type (2019)
  • Figure 62: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value Share, By Distribution Channel (2019)
  • Figure 63: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value Share, By Country (2019)
  • Figure 64: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis, 2015-2019
  • Figure 65: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2030
  • Figure 66 : Middle East and Africa Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Drug Type
  • Figure 67: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Distribution Channel
  • Figure 68: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Attractiveness Analysis, By Country
  • Figure 69: Global Vs. U.S Growth Comparison
  • Figure 70: U.S. Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 71: U.S. Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 72: Global Vs. Canada Growth Comparison
  • Figure 73: Canada Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 74: Canada Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 75: Global Vs. Brazil Growth Comparison
  • Figure 76: Brazil Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 77: Brazil Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 78: Global Vs. Mexico Growth Comparison
  • Figure 79: Mexico Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 80: Mexico Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 81: Global Vs. Germany Growth Comparison
  • Figure 82: Germany Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 83: Germany Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 84: Global Vs. Italy Growth Comparison
  • Figure 85: Italy Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 86: Italy Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 87: Global Vs. France Growth Comparison
  • Figure 88: France Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 89: France Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 90: Global Vs. U.K. Growth Comparison
  • Figure 91: U.K. Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 92: U.K. Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 93: Global Vs. Spain Growth Comparison
  • Figure 94: Spain Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 95: Spain Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 96: Global Vs. Russia Growth Comparison
  • Figure 97: Russia Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 98: Russia Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 99: Global Vs. India Growth Comparison
  • Figure 100: India Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 101: India Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 102: Global Vs. Thailand Growth Comparison
  • Figure 103: Thailand Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 104: Thailand Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 105: Global Vs. Indonesia Growth Comparison
  • Figure 106: Indonesia Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 107: Indonesia Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 108: Global Vs. Malaysia Growth Comparison
  • Figure 109: Malaysia Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 110: Malaysia Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 111: Global Vs. Japan Growth Comparison
  • Figure 112: Japan Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 113: Japan Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 114: Global Vs. Australia Growth Comparison
  • Figure 115: Australia Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 116: Australia Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 117: Global Vs. New Zealand Growth Comparison
  • Figure 118: New Zealand Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 119: New Zealand Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 120 :Global Vs. GCC Countries Growth Comparison
  • Figure 121: GCC Countries Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 122: GCC Countries Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 123: Global Vs. South Africa Growth Comparison
  • Figure 124: South Africa Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 125: South Africa Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
  • Figure 126: Global Vs. China Growth Comparison
  • Figure 127: China Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Drug Type, 2020E
  • Figure 128: China Triple-Negative Breast Cancer Treatment Market Share Analysis (%), By Distribution Channel, 2020E
目次
Product Code: PMRREP14305

Scope of the Report:

A latest publication by Persistence Market Research (PMR) on the global triple-negative breast cancer treatment market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global triple-negative breast cancer treatment market. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, opportunities in the triple-negative breast cancer treatment market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.

Important indicators for the successful growth of the triple-negative breast cancer treatment market are presented in this comprehensive report, which include supply chain analysis, value chain analysis, Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR. This research study can support readers to know the demand for triple-negative breast cancer treatment and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the triple-negative breast cancer treatment market, including triple-negative breast cancer treatment market investors and service providers, and can help them in developing suitable business strategies for development in the market. Insights and findings presented in this PMR study can be leveraged by shareholders in the triple-negative breast cancer treatment market, industry experts, investors, researchers, reporters, as well as business enthusiasts.

Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the triple-negative breast cancer treatment market are also included in the current study. Depending on potential developments in the triple-negative breast cancer treatment market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this triple-negative breast cancer treatment market report, minor companies and new entrants in the breast cancer treatment industry can be aided in making suitable company choices to achieve traction in the triple-negative breast cancer treatment market.

Key Questions Answered:

  • Which regions will continue to remain the most profitable regional market for triple-negative breast cancer treatment market players?
  • Which factors will induce a change in the demand for breast cancer treatment during the assessment period?
  • How will COVID-19 change the trends of the triple-negative breast cancer treatment market?
  • How can market players capture the low-hanging opportunities in the triple-negative breast cancer treatment market in developed regions?
  • What are the winning strategies of stakeholders in the triple-negative breast cancer treatment market to upscale their position in this landscape?
  • What are the restraints that investors need to be aware of and tackle while investing in the triple-negative breast cancer treatment market?
  • What are the developmental trends in the triple-negative breast cancer treatment sectors that will impact the market?
  • How can businesses in the triple-negative breast cancer treatment market avail the growth opportunities in developed and emerging economies?

Research Methodology:

In PMR's study, a unique research methodology is utilized to conduct extensive research on the growth of the triple-negative breast cancer treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the triple-negative breast cancer treatment market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts interviewed specialized industry experts, medical professionals related to triple-negative breast cancer treatment, and key executives of drug development and manufacturing companies, who contributed to the development of this report as a primary resource.

Comprehensive information assessment from primary and secondary resources acts as a validation from companies in the triple-negative breast cancer treatment market, and makes PMR's projections on the growth prospects of the market more accurate and reliable.

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion & Exclusion/ Scope of the Report

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Development Trends
  • 3.3. Key Regulations

4. Market Background

  • 4.1. Macro-Economic Factors
    • 4.1.1. Global GDP Growth Outlook
    • 4.1.2. Per Capita Healthcare Expenditure Outlook
    • 4.1.1. Regional Healthcare Market Outlook
  • 4.2. Forecast Factors - Relevance & Impact
    • 4.2.1. Increasing Expenditure for Cancer Care
    • 4.2.2. Growing Prevalence of Breast Cancer
    • 4.2.3. Advancement in Cancer Treatment
    • 4.2.4. New and Emerging Treatment Options
    • 4.2.5. Potential in Generic Drugs
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunity Analysis
  • 4.4. Value Chain Analysis

5. COVID19 - Impact Analysis

    • 5.1.1. Current COVID19 Statistics and Probable Future Impact
    • 5.1.2. Current GDP Projection and Probable Impact
    • 5.1.3. Current Economic Projection as compared to 2008 Economic analysis
    • 5.1.4. COVID19 and Impact Analysis
      • 5.1.4.1. Revenue By Drug Type
    • 5.1.5. Projected Recovery Quarter
    • 5.1.6. Recovery Scenario - Short term, Midterm and Long Term Impact

6. Key Success Factors.

  • 6.1. Product Adoption / Usage Analysis
  • 6.2. Key Promotional Strategies
  • 6.3. Disease Epidemiology, Key Region
  • 6.4. Reimbursement Guidelines

7. Global Triple-Negative Breast Cancer Treatment Market Pricing Analysis

  • 7.1. Regional Pricing Analysis By Product Type
  • 7.2. Pricing Break-up
    • 7.2.1. Manufacturer Level Pricing
    • 7.2.2. Distributor Level Pricing

8. Global Triple-Negative Breast Cancer Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030

  • 8.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
  • 8.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
    • 8.2.1. Y-o-Y Growth Trend Analysis
    • 8.2.2. Absolute $ Opportunity Analysis

9. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2015 - 2019
  • 9.3. Current and Future Market Size (US$ Mn) and Forecast By Drug Type, 2020 - 2030
    • 9.3.1. Doxorubicin
    • 9.3.2. Cyclophosphamide
    • 9.3.3. Paclitaxel
    • 9.3.4. Docetaxel
    • 9.3.5. Carboplatin/Cisplatin
    • 9.3.6. Others
  • 9.4. Market Attractiveness Analysis Product

10. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015 - 2019
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 - 2030
    • 10.3.1. Hospitals
    • 10.3.2. Cancer Research Institutes
    • 10.3.3. Retail Clinics
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015 - 2019
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020 - 2030
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. South Asia
    • 11.3.5. East Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis By Region

12. North America Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019
  • 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Drug Type
    • 12.3.3. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis

13. Latin America Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019
  • 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030
    • 13.3.1. By Country
      • 13.3.1.1. Brazil
      • 13.3.1.2. Mexico
      • 13.3.1.3. Rest of Latin America
    • 13.3.2. By Drug Type
    • 13.3.3. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis

14. Europe Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019
  • 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. Italy
      • 14.3.1.3. France
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Russia
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Drug Type
    • 14.3.3. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis

15. South Asia Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019
  • 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Thailand
      • 15.3.1.3. Indonesia
      • 15.3.1.4. Malaysia
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Drug Type
    • 15.3.3. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis

16. East Asia Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019
  • 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Drug Type
    • 16.3.3. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis

17. Oceania Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019
  • 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Drug Type
    • 17.3.3. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019
  • 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkey
      • 18.3.1.3. Northern Africa
      • 18.3.1.4. South Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Drug Type
    • 18.3.3. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis

19. Key and Emerging Countries Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

  • 19.1. Introduction
    • 19.1.1. Market Value Proportion Analysis, By Key Countries
    • 19.1.2. Global Vs. Country Growth Comparison
  • 19.2. U.S. Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.2.1. By Drug Type
    • 19.2.2. By Distribution Channel
  • 19.3. Canada Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.3.1. By Drug Type
    • 19.3.2. By Distribution Channel
  • 19.4. Brazil Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.4.1. By Drug Type
    • 19.4.2. By Distribution Channel
  • 19.5. Mexico Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.5.1. By Drug Type
    • 19.5.2. By Distribution Channel
  • 19.6. Germany Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.6.1. By Drug Type
    • 19.6.2. By Distribution Channel
  • 19.7. Italy Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.7.1. By Drug Type
    • 19.7.2. By Distribution Channel
  • 19.8. France Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.8.1. By Drug Type
    • 19.8.2. By Distribution Channel
  • 19.9. U.K. Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.9.1. By Drug Type
    • 19.9.2. By Distribution Channel
  • 19.10. Spain Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.10.1. By Drug Type
    • 19.10.2. By Distribution Channel
  • 19.11. BENELUX Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.11.1. By Drug Type
    • 19.11.2. By Distribution Channel
  • 19.12. Russia Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.12.1. By Drug Type
    • 19.12.2. By Distribution Channel
  • 19.13. India Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.13.1. By Drug Type
    • 19.13.2. By Distribution Channel
  • 19.14. Thailand Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.14.1. By Drug Type
    • 19.14.2. By Distribution Channel
  • 19.15. Indonesia Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.15.1. By Drug Type
    • 19.15.2. By Distribution Channel
  • 19.16. Malaysia Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.16.1. By Drug Type
    • 19.16.2. By Distribution Channel
  • 19.17. China Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.17.1. By Drug Type
    • 19.17.2. By Distribution Channel
  • 19.18. Japan Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.18.1. By Drug Type
    • 19.18.2. By Distribution Channel
  • 19.19. South Korea Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.19.1. By Drug Type
    • 19.19.2. By Distribution Channel
  • 19.20. Australia Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.20.1. By Drug Type
    • 19.20.2. By Distribution Channel
  • 19.21. New Zealand Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.21.1. By Drug Type
    • 19.21.2. By Distribution Channel
  • 19.22. GCC Countries Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.22.1. By Drug Type
    • 19.22.2. By Distribution Channel
  • 19.23. Turkey Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.23.1. By Drug Type
    • 19.23.2. By Distribution Channel
  • 19.24. Northern Africa Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.24.1. By Drug Type
    • 19.24.2. By Distribution Channel
  • 19.25. South Africa Triple-Negative Breast Cancer Treatment Market Analysis
    • 19.25.1. By Drug Type
    • 19.25.2. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Structure Analysis by Tier of Companies
  • 20.2. Market Share Analysis for Top Players
  • 20.3. Market Concentration
  • 20.4. Market Presence Analysis
    • 20.4.1. By Regional footprint of Players
    • 20.4.2. Product foot print by Players
    • 20.4.3. Channel Foot Print by Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. AstraZeneca plc.
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.1.4. Sales Footprint
      • 21.3.1.5. Strategy Overview
        • 21.3.1.5.1. Marketing Strategy
        • 21.3.1.5.2. Product Strategy
        • 21.3.1.5.3. Channel Strategy
    • 21.3.2. Pfizer, Inc.
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.2.4. Sales Footprint
      • 21.3.2.5. Strategy Overview
        • 21.3.2.5.1. Marketing Strategy
        • 21.3.2.5.2. Product Strategy
        • 21.3.2.5.3. Channel Strategy
    • 21.3.3. F. Hoffman - La Roche Ltd.
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.3.4. Sales Footprint
      • 21.3.3.5. Strategy Overview
        • 21.3.3.5.1. Marketing Strategy
        • 21.3.3.5.2. Product Strategy
        • 21.3.3.5.3. Channel Strategy
    • 21.3.4. Bristol-Myers Squibb Company
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.4.4. Sales Footprint
      • 21.3.4.5. Strategy Overview
        • 21.3.4.5.1. Marketing Strategy
        • 21.3.4.5.2. Product Strategy
        • 21.3.4.5.3. Channel Strategy
    • 21.3.5. Novartis AG
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.5.4. Sales Footprint
      • 21.3.5.5. Strategy Overview
        • 21.3.5.5.1. Marketing Strategy
        • 21.3.5.5.2. Product Strategy
        • 21.3.5.5.3. Channel Strategy
    • 21.3.6. Mylan N.V.
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.6.4. Sales Footprint
      • 21.3.6.5. Strategy Overview
        • 21.3.6.5.1. Marketing Strategy
        • 21.3.6.5.2. Product Strategy
        • 21.3.6.5.3. Channel Strategy
    • 21.3.7. Eli Lilly and Company
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.7.4. Sales Footprint
      • 21.3.7.5. Strategy Overview
        • 21.3.7.5.1. Marketing Strategy
        • 21.3.7.5.2. Product Strategy
        • 21.3.7.5.3. Channel Strategy
    • 21.3.8. Celgene Corporation
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.8.4. Sales Footprint
      • 21.3.8.5. Strategy Overview
        • 21.3.8.5.1. Marketing Strategy
        • 21.3.8.5.2. Product Strategy
        • 21.3.8.5.3. Channel Strategy
    • 21.3.9. Sanofi S.A.
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.9.4. Sales Footprint
      • 21.3.9.5. Strategy Overview
        • 21.3.9.5.1. Marketing Strategy
        • 21.3.9.5.2. Product Strategy
        • 21.3.9.5.3. Channel Strategy
    • 21.3.10. Johnson & Johnson Services, Inc.
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
      • 21.3.10.4. Sales Footprint
      • 21.3.10.5. Strategy Overview
        • 21.3.10.5.1. Marketing Strategy
        • 21.3.10.5.2. Product Strategy
        • 21.3.10.5.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.